Terms: = Head and neck cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
242 results:
1. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Kato T; Mizuno R; Miyake H
Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663
[TBL] [Abstract] [Full Text] [Related]
2. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity.
Masaki C; Shioya J; Sugino K; Terasawa Y; Yokotsuka S; Nakata M; Kitagawa W; Ito K
Support Care Cancer; 2023 Nov; 31(12):729. PubMed ID: 38017341
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of an individualized angiogenesis and tumor-infiltrating lymphocytes prognostic signature in nasopharyngeal carcinoma.
Zhang R; Liao X; Zhang B; Huang X; Qin G; Kong X; Xie Y; Mo Y; Dai J; Gan C; Luo Z; Lu J; Jiang W
Pathol Res Pract; 2024 Jan; 253():154936. PubMed ID: 38006840
[TBL] [Abstract] [Full Text] [Related]
4. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid cancer Treated With vegfr TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract] [Full Text] [Related]
5. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Hanna GJ; Ahn MJ; Muzaffar J; Keam B; Bowles DW; Wong DJ; Ho AL; Kim SB; Worden F; Yun T; Meng X; Van Tornout JM; Conlan MG; Kang H
Clin Cancer Res; 2023 Nov; 29(22):4555-4563. PubMed ID: 37643133
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of vegfr2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma.
Onda M; Ota A; Ito K; Ono T; Karnan S; Kato M; Kondo S; Furuhashi A; Hayashi T; Hosokawa Y; Kazaoka Y
Cancer Med; 2023 Aug; 12(15):16416-16430. PubMed ID: 37341071
[TBL] [Abstract] [Full Text] [Related]
7. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ; Liao CY; Karrison T; de Souza JA; Worden FP; Libao B; Krzyzanowska MK; Hayes DN; Winquist E; Saloura V; Prescott K; Villaflor VM; Seiwert TY; Schechter RB; Stadler WM; Cohen EEW; Vokes EE
Ann Oncol; 2023 Aug; 34(8):714-722. PubMed ID: 37182801
[TBL] [Abstract] [Full Text] [Related]
8. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract] [Full Text] [Related]
9. Perioperative Tailored treatments for Gastric cancer: Times Are Changing.
Lavacchi D; Fancelli S; Buttitta E; Vannini G; Guidolin A; Winchler C; Caliman E; Vannini A; Giommoni E; Brugia M; Cianchi F; Pillozzi S; Roviello G; Antonuzzo L
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902306
[TBL] [Abstract] [Full Text] [Related]
10. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto R; Sousa LG; Feng L; Mott F; Blumenschein G; Altan M; Bell D; Bonini F; Li K; Marques-Piubelli ML; Dal Lago EA; Johnson JJ; Mitani Y; Godoy M; Lee A; Kupferman M; Hanna E; Glisson BS; Elamin Y; El-Naggar A
J Clin Oncol; 2023 May; 41(15):2843-2851. PubMed ID: 36898078
[TBL] [Abstract] [Full Text] [Related]
11. Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid cancer.
Ly NS; Li J; Faggioni R; Roskos LK; Brose MS
Clin Pharmacokinet; 2023 Apr; 62(4):587-598. PubMed ID: 36869986
[TBL] [Abstract] [Full Text] [Related]
12. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
13. Systemic and Targeted Therapies in Adenoid Cystic Carcinoma.
Kacew AJ; Hanna GJ
Curr Treat Options Oncol; 2023 Jan; 24(1):45-60. PubMed ID: 36637743
[TBL] [Abstract] [Full Text] [Related]
14. Guggulsterone Promotes Nasopharyngeal Carcinoma Cells Exosomal Circfip1L1 to Mediate miR-125a-5p/VEGFA Affecting Tumor Angiogenesis.
Zhou T; Zhao S; Tang S; Wang Y; Wu R; Zeng X; Yang P; Zhang X; Tian X
Curr Mol Pharmacol; 2023; 16(8):870-880. PubMed ID: 36635928
[TBL] [Abstract] [Full Text] [Related]
15. The efficacy and safety of VEGF/vegfr inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A meta-analysis.
Xue S; Song G; Zhu Y; Zhang N; Tan Y
Oral Oncol; 2022 Dec; 135():106231. PubMed ID: 36327674
[TBL] [Abstract] [Full Text] [Related]
16. Artemisinin suppressed tumour growth and induced vascular normalisation in oral squamous cell carcinoma via inhibition of macrophage migration inhibitory factor.
Yu XH; Wu JB; Fan HY; Dai L; Xian HC; Chen BJ; Liao P; Huang MC; Pang X; Zhang M; Liang XH; Tang YL
Oral Dis; 2024 Mar; 30(2):363-375. PubMed ID: 36321394
[TBL] [Abstract] [Full Text] [Related]
17. Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in cancer Therapy.
Gales L; Forsea L; Mitrea D; Stefanica I; Stanculescu I; Mitrica R; Georgescu M; Trifanescu O; Anghel R; Serbanescu L
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143915
[TBL] [Abstract] [Full Text] [Related]
18. Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
Hagege A; Saada-Bouzid E; Ambrosetti D; Rastoin O; Boyer J; He X; Rousset J; Montemagno C; Doyen J; Pedeutour F; Parola J; Bourget I; Luciano F; Bozec A; Cao Y; Pagès G; Dufies M
Cell Rep Med; 2022 Sep; 3(9):100659. PubMed ID: 36130479
[TBL] [Abstract] [Full Text] [Related]
19. Identifying key mutations of radioresponsive genes in esophageal squamous cell carcinoma.
Xu X; Wang Y; Bai Y; Lu J; Guo Y; Wang X; Rong L; Tang J; Ma X; Ma J; Zhang L
Front Immunol; 2022; 13():1001173. PubMed ID: 36119057
[TBL] [Abstract] [Full Text] [Related]
20. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and vegfr2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.
Ju WT; Xia RH; Zhu DW; Dou SJ; Zhu GP; Dong MJ; Wang LZ; Sun Q; Zhao TC; Zhou ZH; Liang SY; Huang YY; Tang Y; Wu SC; Xia J; Chen SQ; Bai YZ; Li J; Zhu Q; Zhong LP
Nat Commun; 2022 Sep; 13(1):5378. PubMed ID: 36104359
[TBL] [Abstract] [Full Text] [Related]
[Next]
